Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Acquisitions & Divestments: 2020-2024

Historic Change in Acquisitions & Divestments for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $327.8 million.

  • Tango Therapeutics' Change in Acquisitions & Divestments fell 8.57% to $66.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $269.8 million, marking a year-over-year decrease of 17.76%. This contributed to the annual value of $327.8 million for FY2024, which is 7.29% down from last year.
  • Latest data reveals that Tango Therapeutics reported Change in Acquisitions & Divestments of $327.8 million as of FY2024, which was down 7.29% from $353.5 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' Change in Acquisitions & Divestments peaked at $353.5 million during FY2023, and registered a low of $63.2 million during FY2020.
  • In the last 3 years, Tango Therapeutics' Change in Acquisitions & Divestments had a median value of $327.8 million in 2024 and averaged $308.0 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 201.75% in 2021, then fell by 7.29% in 2024.
  • Over the past 5 years, Tango Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $63.2 million in 2020, then soared by 201.75% to $190.8 million in 2021, then grew by 27.17% to $242.6 million in 2022, then skyrocketed by 45.73% to $353.5 million in 2023, then declined by 7.29% to $327.8 million in 2024.